DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment.

Slides:



Advertisements
Similar presentations
Branko N Huisa M.D. Assistant Professor of Neurology UNM Stroke Center.
Advertisements

Trademarks may be registered and are the property of their respective owners. Today’s discussion may regard information or indications not evaluated by.
The DRASTIC Trial. Dutch Renal Artery Stenosis Intervention Cooperative Reference van Jaarsveld BC, Krijnen P, Derkx FHM, et al. Resistance to antihypertensive.
Resistant hypertension increases patients’ cardiovascular risk 30% of all treated patients develop resistant hypertension [1-5]. Resistant hypertension.
Hypertension and The Kidney Update: Clinical Trials Paul J. Scheel, Jr., M.D. Director, Division of Nephrology The Johns Hopkins University School of Medicine.
NHANES III Prevalence of Hypertension* According to BMI
Maximum home blood pressure: a novel indicator of target-organ damage in hypertension  Blood pressure variability has recently been shown to be a strong.
Ambulatory blood pressure as a predictor of cardiovascular risk: What’s new?
The TRial Of Preventing HYpertension (TROPHY) TROPHY.
Aim To determine the effects of a Coversyl- based blood pressure lowering regimen on the risk of recurrent stroke among patients with a history of stroke.
לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים ונורמוטנסיבים) עם מיקרואלבומינוריה לדיובן הגנה כלייתית מוכחת בחולי סכרת מסוג 2, (היפרטנסיבים.
Federal Study of Adherence to Medications (FAME) Trial Presented at The American Heart Association Annual Scientific Session 2006 Presented by Dr. Allen.
Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:
A Global Perspective on Blood Pressure Treatment and Control in a Referred Cohort of Hypertensive Patients Bramlage P, et al. J Clin Hyper. doi: /j x.
A Controlled Trial of Renal Denervation for Resistant Hypertension
Objective: To asses the efficacy of hydrochlorothiazide on 24-h blood pressure (BP) control.Methods: Review of all the randomized trials that assessed.
Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension Featured Article: Ilkka Tikkanen, Kirsi Narko, Cordula Zeller, Alexandra.
Slide Source: Lipids Online Slide Library Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) Design Sever PS et al. J Hypertens 2001;19:1139–1147.
Renal denervation for resistant hypertension: it’s time to reconsider!
Initial combination therapy reduces the risk of cardiovascular events in hypertensive patients Gradman AH, Parisé H, Lefebvre P, Falvey H, Lafeuille MH,
Long-term prognostic value of white coat hypertension: an insight from diagnostic use of both ambulatory and home blood pressure measurements Reference:
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Impact of Renal Denervation on 24-Hour Ambulatory.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Renal Denervation in Moderate Treatment-Resistant.
Date of download: 5/29/2016 Copyright © The American College of Cardiology. All rights reserved. From: Safety and Efficacy of Low Blood Pressures Among.
Study design: a randomized placebo- controlled crossover trial of 2 periods of 4 weeks Nicole A.J. van der Linde, et al. Hypertension 2006;47;
Date of download: 7/6/2016 Copyright © The American College of Cardiology. All rights reserved. From: Externally Delivered Focused Ultrasound for Renal.
Dr John Cox Diabetes in Primary Care Conference Cork
Prairie Cardiovascular, Springfield, IL US
Copyright © 2010 American Medical Association. All rights reserved.
FDA Pathway to Approval: Clinical Requirements for Renal Denervation
Eoin O’Brien, DSc, MD, Eamon Dolan, MD, FRCPI  Clinical Therapeutics 
Critical Appraisal of the Current Ongoing Study Designs
From ESH 2016 | POS 7D: Jan Rosa, MD
Trial profile for the pharmacokinetics and pharmacodynamics study in patients with dyslipidaemia (A) and the ambulatory blood pressure study (B) *Participants.
CORAL Trial design: Patients with renal artery stenosis and hypertension or chronic kidney disease were randomized to renal artery stenting (n = 467) vs.
Flowchart of participants
BEAUTY Trial: Hypertension Control Not Improved with Hemodynamic Monitoring From ESH 2016 | LB 3: Pierre Boutouyrie, MD, PhD INSERM, Université Paris Descartes,
by Michael D. Elliott, Ajoy Kapoor, Michele A. Parker, Dixon B
Aliskiren and Valsartan for Antihypertensive Therapy Trial
The Ardian Catheter Based Approach to Renal Denervation to Treat Refractory HTN: Results of the EU Randomized Clinical Trial Krishna Rocha-Singh, M.D.,
Resistant Hypertension, Time‐Updated Blood Pressure Values and Renal Outcome in Type 2 Diabetes Mellitus by Francesca Viazzi, Pamela Piscitelli, Antonio.
Circ Cardiovasc Qual Outcomes
(CMR vs. guidelines, p < 0.001)
by Katie Ayers, Loretta M. Byrne, Anthony DeMatteo, and Nancy J. Brown
Renal Denervation Two Late-Breaking Clinical Trials.
Oana Dickinson et al. JACEP 2016;2:
AcoArt I Trial design: Patients with femoropopliteal artery disease were randomized to paclitaxel-coated balloon angioplasty (n = 100) vs. standard peripheral.
Cholesterol and blood pressure values at baseline and after 15 days of dark-chocolate and white-chocolate consumption Characteristic Dark chocolate before.
Resistant Hypertension: Initial Combinations of Medications
MARFAN SARTAN Trial design: Marfan patients were randomized to losartan (n = 153) vs. placebo (n = 150). The dose of losartan was 50 mg for those
Losartan vs. Atenolol in Marfan Syndrome
PREMIER: Rate of hypertension at 18 months
VALUE Trial design: Hypertensive patients at high cardiovascular risk were randomized to valsartan (n = 7,649) vs. amlodipine (n = 7,596). Results (p =
Why double blind, controlled randomized trials?
CANOA Trial design: Patients undergoing percutaneous closure of an ASD with the Amplatzer Septal Occluder were randomized to aspirin 80 mg plus clopidogrel.
End point Net change with soy supplements vs control (95% CI) p
Controlling Elevated Blood Pressure
Adjusted relative risk for developing end-stage renal disease (ESRD) associated with blood-pressure level BP level (mm Hg) Adjusted relative risk 95%
CHAMPION Trial design: Patients with recent hospitalization for heart failure were implanted with a pulmonary artery pressure monitor and randomized so.
Ambulatory BP Monitoring vs Office BP
Volume 377, Issue 9771, Pages (March 2011)
Ambulatory BP Monitoring vs Office BP
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,
Flow chart of the 1683 study members at age 60–64 years by hypertension (HT) status. Flow chart of the 1683 study members at age 60–64 years by hypertension.
Demographic and Clinical Characteristics (means ± SD or %) of Subjects in Different Office SBP and DBP Categories Mancia G et al Hypertension. 2005;45:1072.
End point Valsartan Valsartan+HCTZ p
Mean Pulmonary Artery Pressure Change Post-Thrombectomy Average pre-procedural mean pulmonary artery pressure (mPAP) in patients with pulmonary hypertension.
Effects of placebo or carvedilol CR on 24-hour mean systolic blood pressure and diastolic blood pressure obtained by ambulatory monitoring in hypertensive.
The combined effects of low sodium and the DASH diet according to baseline blood pressure. The combined effects of low sodium and the DASH diet according.
Average change in blood pressure (BP) from recruitment to 6-month postrecruitment in intervention and control patients >50 years included due to having.
Presentation transcript:

DENERHTN Trial design: Patients with resistant hypertension were randomized to renal denervation plus standardized stepped-care antihypertensive treatment (n = 53) vs. standardized stepped-care antihypertensive treatment alone (n = 53). (p = 0.033) Results Change in systolic blood pressure from baseline to 6 months: -15.8 mm Hg in the renal denervation group vs. -9.9 mm Hg in the standardized antihypertensive treatment alone group (p = 0.033) Change in SBP mm Hg -9.9 Conclusions Among patients with resistant hypertension, renal denervation plus standardized antihypertensive treatment was more effective at reducing ambulatory, but not office blood pressure, compared with standardized antihypertensive treatment alone -15.8 Anti-hypertensive treatment alone Renal denervation Azizi M, et al., Lancet 2015;385:1957-65